- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00361894
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)
October 24, 2014 updated by: Bayer
RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2531
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Wien, Austria, 1140
-
-
Oberösterreich
-
Linz, Oberösterreich, Austria, 4010
-
-
Steiermark
-
Graz, Steiermark, Austria, 8036
-
-
Tirol
-
Innsbruck, Tirol, Austria, 6020
-
-
-
-
-
Antwerpen, Belgium, 2020
-
Hasselt, Belgium, 3500
-
Liege, Belgium, 4000
-
Merksem, Belgium, 2170
-
Pellenberg, Belgium, 3212
-
Reet, Belgium, 2840
-
Roeselare, Belgium, 8800
-
-
-
-
British Columbia
-
Penticton, British Columbia, Canada, V2A 5C8
-
-
New Brunswick
-
St. John, New Brunswick, Canada, E2L 4L2
-
-
Ontario
-
Burlington, Ontario, Canada, L7R 4C4
-
Kitchener, Ontario, Canada, N2G 1G3
-
Oakville, Ontario, Canada, L6J 3M5
-
Oshawa, Ontario, Canada, L1G 2B9
-
Ottawa, Ontario, Canada, K1Y 4E9
-
Peterborough, Ontario, Canada, K9J 7C6
-
Scarborough, Ontario, Canada, M1E 4B9
-
Windsor, Ontario, Canada, N9A 1E1
-
-
-
-
-
Beijing, China, 100044
-
Beijing, China, 100853
-
Beijing, China, 100035
-
Shanghai, China, 200032
-
Shanghai, China, 200233
-
Shanghai, China, 200025
-
-
-
-
-
Bogotá, Colombia
-
Cali, Colombia
-
Medellín, Colombia
-
-
-
-
-
Brno, Czech Republic, 62500
-
Chomutov, Czech Republic, 430 01
-
Havlickuv Brod, Czech Republic, 580 01
-
Jihlava, Czech Republic, 586 01
-
Kolin, Czech Republic, 280 00
-
Pardubice, Czech Republic, 530 03
-
Plzen, Czech Republic, 304 60
-
-
Tschechien
-
Praha 8, Tschechien, Czech Republic, 180 81
-
-
-
-
-
Frederiksberg, Denmark, 2000
-
Hellerup, Denmark, 2900
-
Herlev, Denmark, 2730
-
Hørsholm, Denmark, DK-2970
-
Silkeborg, Denmark, 8600
-
-
-
-
-
Bois-guillaume, France, 76230
-
Clermont Ferrand, France, 63050
-
Lievin, France, 62806
-
Marseille, France, 13008
-
Monaco, France, 98000
-
Nantes Cedex 2, France, 44277
-
Nice, France, 06002
-
Nice, France, 06000
-
Paris, France, 75674
-
Paris Cedex 14, France, 75877
-
Paris Cedex 19, France, 75019
-
Paris Cedex 20, France, 75960
-
Soyaux, France, 16800
-
Vandoeuvre Les Nancy, France, 54511
-
-
-
-
-
Bremen, Germany, 28205
-
-
Baden-Württemberg
-
Bad Mergentheim, Baden-Württemberg, Germany, 97980
-
Rheinfelden, Baden-Württemberg, Germany, 79618
-
-
Bayern
-
Fürth, Bayern, Germany, 90766
-
Garmisch-Partenkirchen, Bayern, Germany, 82467
-
Würzburg, Bayern, Germany, 97080
-
-
Brandenburg
-
Sommerfeld, Brandenburg, Germany, 16766
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60528
-
Frankfurt, Hessen, Germany, 65929
-
-
Nordrhein-Westfalen
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
-
Witten, Nordrhein-Westfalen, Germany, 58448
-
-
-
-
-
Beer Sheva, Israel, 84101
-
Haifa, Israel, 31096
-
Holon, Israel, 58100
-
Kfar Saba, Israel, 44281
-
Tel Aviv, Israel, 64239
-
Tel Hashomer, Israel, 52621
-
Zerifin, Israel, 70300
-
-
-
-
-
Bologna, Italy, 40136
-
Firenze, Italy, 50139
-
Lecco, Italy, 23900
-
Padova, Italy, 35127
-
Parma, Italy, 43100
-
Roma, Italy, 00168
-
Udine, Italy, 33100
-
Varese, Italy, 21100
-
-
Milano
-
San Donato Milanese, Milano, Italy, 20097
-
-
Padova
-
Abano Terme, Padova, Italy, 35031
-
-
Perugia
-
Gubbio, Perugia, Italy, 06024
-
-
Sassari
-
Alghero, Sassari, Italy, 07041
-
-
-
-
Chihuahua
-
Chihuahua, Chih., Chihuahua, Mexico, 31000
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44280
-
-
Sonora
-
Hermosillo, Sonora, Mexico, 83000
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
-
Hilversum, Netherlands, 1213 XZ
-
Hoofddorp, Netherlands, 2134 TM
-
Leiden, Netherlands, 2334 CK
-
Nijmegen, Netherlands, 6522 JV
-
OSS, Netherlands, 5342 BT
-
Zwolle, Netherlands, 8011 JW
-
-
-
-
-
Elverum, Norway, 2409
-
Gjövik, Norway, 2819
-
Kongsvinger, Norway, 2212
-
Lillehammer, Norway, 2609
-
Namsos, Norway, 7800
-
-
-
-
-
Callao, Peru, CALLAO 2
-
Lima, Peru, Lima 11
-
Lima, Peru, Lima 1
-
-
-
-
-
Bialystok, Poland, 15-276
-
Bydgoszcz, Poland, 85-094
-
Gdansk, Poland, 80-803
-
Krakow, Poland, 31-826
-
Lodz, Poland, 91-002
-
Lublin, Poland, 20-090
-
Lublin, Poland, 20-718
-
Szczecin, Poland, 71-252
-
Warszawa, Poland, 02-637
-
Warszawa, Poland, 00-909
-
-
-
-
Freestate
-
Bloemfontein, Freestate, South Africa, 9300
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2132
-
Pretoria, Gauteng, South Africa, 0084
-
Pretoria, Gauteng, South Africa
-
Pretoria, Gauteng, South Africa, PRETORIA
-
Randburg, Gauteng, South Africa, 2125
-
-
Kwa Zulu-Natal
-
Newcastle, Kwa Zulu-Natal, South Africa, 2940
-
-
KwaZulu Natal
-
Durban, KwaZulu Natal, South Africa, 4030
-
-
Western Cape
-
Somerset West, Western Cape, South Africa, 7130
-
Worcester, Western Cape, South Africa, 6850
-
-
-
-
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08035
-
Barcelona, Spain, 08006
-
Castellón de la Plana, Spain, 12004
-
Jaén, Spain, 23007
-
Madrid, Spain, 28040
-
Pamplona, Spain, 31008
-
Valencia, Spain, 46010
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
-
-
-
-
-
Falköping, Sweden, 521 85
-
Göteborg, Sweden, 416 85
-
Halmstad, Sweden, 301 85
-
Hässleholm, Sweden, 281 25
-
Jönköping, Sweden, 551 85
-
Kungälv, Sweden, 442 83
-
Lidköping, Sweden, 531 85
-
Varberg, Sweden, 432 81
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:- Male and female patients aged 18 years or above- Patients scheduled for elective total knee replacement Exclusion Criteria:- Active bleeding or high risk of bleeding contraindicating treatment with LMWH- Contraindication listed in the labeling or conditions precluding subject treatment with enoxaparin or requiring dose adjustment (e.g.
severe renal impairment, please refer to the local label of enoxaparin in your country)- Conditions prohibiting bilateral venography (e.g.
amputation of 1 leg, allergy to contrast media)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Arm 2
|
Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
|
|
Experimental: Arm 1
|
10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Treatment-emergent major bleedings
Time Frame: From first dose of double-blind study medication to up to two days after last dose of double-blind study medication
|
From first dose of double-blind study medication to up to two days after last dose of double-blind study medication
|
|
Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
|
Incidence of symptomatic VTE (DVT, PE)
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
|
Incidence of DVT (total, proximal, distal)
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
|
Incidence of symptomatic VTE during follow-up
Time Frame: Follow-up period: following 13+/-4 days
|
Follow-up period: following 13+/-4 days
|
|
The composite endpoint comprising major VTE and treatment-emergent major bleeding
Time Frame: For major VTE, treatment period: up to Day 13+/-4 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
|
For major VTE, treatment period: up to Day 13+/-4 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
|
|
Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
|
Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death
Time Frame: Treatment period: up to Day 13+/-4
|
Treatment period: up to Day 13+/-4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
August 8, 2006
First Submitted That Met QC Criteria
August 8, 2006
First Posted (Estimate)
August 9, 2006
Study Record Updates
Last Update Posted (Estimate)
October 27, 2014
Last Update Submitted That Met QC Criteria
October 24, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Venous Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Enoxaparin
Other Study ID Numbers
- 11356 (Registry Identifier: DAIDS ES Registry Number)
- EudraCT: 2005-004620-40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.